Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | |
---|---|---|---|---|---|
Risk with usual care | Risk with Transitional are intervention (ver. 1) | ||||
Readmission (Duration of data collection: 12 weeks and more) | 333 per 1,000 | 223 per 1,000 (163 to 307) | RR 0.67 (0.49 to 0.92) | 3739 (9 RCTs) | ⨁⨁⨁◯ Moderatea |
Readmission: Subgroup (Duration of intervention: within six weeks versus seven weeks and more) Data collection duration for 3 RCTs [28, 30, 35]: less than 12 weeks | 187 per 1,000 | 131 per 1,000 (97 to 172) | RR 0.70 (0.52 to 0.92) | 4803 (13 RCTs) | ⨁⨁◯◯ Moderateb, d |
ED visit | 149 per 1,000 | 94 per 1,000 (73 to 121) | RR 0.63 (0.49 to 0.81) | 3464 (4 RCTs) | ⨁⨁⨁⨁ High |
Quolity of life: SF-36 -Mental component 2–4 weeks | The mean quolity of life: SF-36 -Mental component 2–4 weeks was 0 | MD 0.72 higher (0.34 higher to 1.11 higher) | - | 449 (3 RCTs) | ⨁⨁⨁◯ Moderatec |
Quality of life: Subgroup analysis of SF-36 subscale (Up to 5 weeks) | The mean quality of life: SF-36(Up to 5 weeks) was 0 | MD 1.27 higher (0.52 higher to 2.02 higher) | - | 225 (2 RCTs)1) | ⨁⨁◯◯ Lowb, c |
Quality of life: Subgroup analysis of SF-36 subscale (6weeks and more) Sensitvity analysis | The mean quality of life: SF-36(6weeks and more) Sensitvity analysis was 0 | MD 2.46 higher (1.67 higher to 3.25 higher) | - | 225 (2 RCTs) 1) | ⨁⨁◯◯ Lowb, c |